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Abstract
Examination of the role of Ca2-binding proteins (CaBPs) in mammalian retinal neurons has yielded new insights into the
function of these proteins in normal and pathological states. In the last 8 years, studies on guanylate cyclase (GC) regulation
by three GC-activating proteins (GCAP1^3) led to several breakthroughs, among them the recent biochemical analysis of
GCAP1(Y99) mutants associated with autosomal dominant cone dystrophy. Perturbation of Ca2 homeostasis controlled by
mutant GCAP1 in photoreceptor cells may result ultimately in degeneration of these cells. Here, detailed analysis of
biochemical properties of GCAP1(P50L), which causes a milder form of autosomal dominant cone dystrophy than
constitutive active Y99C mutation, showed that the P50L mutation resulted in a decrease of Ca2-binding, without changes
in the GC activity profile of the mutant GCAP1. In contrast to this biochemically well-defined regulatory mechanism that
involves GCAPs, understanding of other processes in the retina that are regulated by Ca2 is at a rudimentary stage.
Recently, we have identified five homologous genes encoding CaBPs that are expressed in the mammalian retina. Several
members of this subfamily are also present in other tissues. In contrast to GCAPs, the function of this subfamily of
calmodulin (CaM)-like CaBPs is poorly understood. CaBPs are closely related to CaM and in biochemical assays CaBPs
substitute for CaM in stimulation of CaM-dependent kinase II, and calcineurin, a protein phosphatase. These results suggest
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that CaM-like CaBPs have evolved into diverse subfamilies that control fundamental processes in cells where they are
expressed. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Ca2 ions play an important role in many biolog-
ical systems [2^5]. Among these, the retina, as part of
the brain, serves as a model system to understand
more complex neuronal organizations. The multicel-
lular layered organization of the retina, availability
of single cell recordings, quanti¢cation of light stim-
uli, and advances in biochemical and genetic meth-
ods provide unprecedented opportunities to under-
stand signal transduction events. Progress in
understanding of G-protein-coupled receptor sys-
tems, and identi¢cation of the architecture of neuro-
nal connectivity are only few examples where studies
on the retina paved the way in understanding other
systems. Another active research area involves regu-
lation of retinal processes by Ca2 and Ca2-binding
proteins (CaBPs) (reviewed in [6]).
A great deal has been learned from studies on
Ca2 e¡ects of retinal physiology, and in particular,
on regulation of phototransduction in photoreceptor
cells [7^11]. Several novel subfamilies of CaBPs re-
lated to calmodulin (CaM) were discovered including
recoverin [12], guanylate cyclase (GC)-activating pro-
teins (GCAPs) [1,13^17], hippocalcin-like CaBPs
[18,19], or CaM-like CaBPs [1] (Fig. 1A). Some of
these proteins appear to play important functions in
the physiology of neurons in other tissues [18^28].
Systematic work on GCAPs over the last 8 years
established rapid progress in understanding their
physiological function, structural organization, and
potential implication in human pathologies (reviewed
in [6,11]). Information on CaM-like CaBPs in the
retina emerged only recently, and we are only begin-
ning to understand the role of these proteins in var-
ious pathways. Both groups of proteins, GCAPs and
CaBPs, appear to be related to an ancestral CaM-
like CaBP containing four EF hand loops for Ca2-
binding. During evolution, selective elimination of
one or two EF hand loops led to creation of novel
properties and functions (Fig. 1B). In some genes
encoding these proteins, point mutations lead to al-
tered functions causing retina disease, an interesting
example being GCAP1(Y99C) linked to autosomal
cone dystrophy [29].
In this communication, we present data related to
two subfamilies of CaBPs, GCAPs and CaBPs, to
illustrate the di¡erent extend of progress made on
the understanding of the role of these proteins in
the retinal neurons and in human pathologies.
2. Materials and methods
2.1. Expression of bovine GC1 in HEK293 cells
Bovine GC1 was expressed in HEK293 cells using
the Bac-to-Bac expression system (Life Technologies,
Inc.). To replace the baculovirus polyhedrin pro-
moter with the CMV promoter, a fragment BglII^
XhoI from the pcDNA3.1 vector (Invitrogen) cover-
ing the pCMV promoter was ¢rst cloned between the
sites SnaBI and BamHI of pFastBac, yielding the
vector pFastCMV. The coding sequence of bovine
GC1, previously subcloned from pSVL-ROS-GC
[30] (obtained from Dr. R. Sharma) in pUC19, was
then transferred as a fragment EcoRI^EcoRI in the
EcoRI site of pFastCMV expression vector. The ex-
pression cassette was then transferred into the bacu-
lovirus shuttle vector by transposition as described
by the manufacturer. After ampli¢cation, the re-
combinant baculoviruses were concentrated by cen-
trifugation at 80 000Ug for 1 h at 4‡C and resus-
pended in phosphate-bu¡ered saline. HEK293 were
then infected with the concentrated recombinant ba-
culoviruses and the expression of recombinant pro-
teins was tested 1 day after infection. The cells were
harvested, washed with 10 mM BTP, pH 7.5, con-
taining 100 mM NaCl, and resuspended at V0.5
mg/ml for the GC assays.
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2.2. Expression and puri¢cation of bovine and human
GCAP1
The bovine GCAP1 coding sequence was ampli¢ed
by PCR with primers, which inserted His6-tag before
the stop codon. The resulting fragment was cloned
into pPCR-Script Amp SK(+) (Stratagene). The
transfer vector expressing bGCAP1-His6 was con-
structed by subcloning a NotI^BamHI fragment
into corresponding sites of the pVL1392 insect cell
vector. The transfer vector expressing human
GCAP1 (hGCAP1) was constructed as described
[31]. High Five insect cells from cabbage looper
were transfected with baculovirus vector (pVL1393)
carrying the cloned GCAP1 cDNA. Cells were cul-
tured 96 h, homogenized in water containing 2 mM
benzamidine and centrifuged at 100 000Ug for 10
min at 4‡C. The supernatant was used as a source
of GCAPs. GCAP1 properties were studied from at
least two independent preparations. GCAP1-His6
and its mutant proteins used in the GC assays were
puri¢ed from insect cells on Ni2-nitrilotriacetic acid
(Ni2-NTA) columns in non-denaturing conditions
according to the manufacturer’s protocol (Qiagen).
[Ca2]free was adjusted by EGTA/Ca2 bu¡er as pre-
viously described [32].
2.3. Expression and puri¢cation of bovine and human
GCAP1(P50L)
The P50L mutations were generated in bovine and
human GCAP1 with QuikChange1 site-directed mu-
Fig. 1. Phylogenetic analysis and arrangement of functional EF hands in human CaBPs. A: The dendrogram. The ¢gure was gener-
ated using Omiga 2.0 (Oxford Molecular) and CLUSTAL W. For analysis, three gene subfamilies were selected, the GCAPs, the hip-
pocalcins/hippocalcin-like proteins (HPL), and CaM-like CaBPs. The accession numbers of respective proteins are followed by an ab-
breviated name. A sequence alignment of CaM-like CaBPs from various mammalian species is shown in Fig. 5. Abbreviations:
FREQ, frequenin; VIS, visinin; REC, recoverin; and CaM. B: Simpli¢ed one-dimensional arrangement of functional EF hands in
various CaBP subfamilies. Semitransparent boxes represent non-functional EF hands; solid boxes indicate the presence of consensus
sequences consistent with Ca2-binding. Presence of a myristoylation site is indicated by an N-terminal box. A ¢lled box indicates
presence of a myristoylation site only in some family members.
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tagenesis kit (Stratagene). The mutagenic primers
were: 5P-G AAC CTG AGC CTG TCG GCC
AGC CAG (sense) and 5P-CTG GCT GGC CGA
CAG GCT CAG GTT C (antisense). All mutant
DNA constructs were puri¢ed and sequenced as
described previously [31]. bGCAP1(P50L) and
hGCAP1(P50L) were puri¢ed by Ni2-NTA metal
a⁄nity chromatography from Qiagen. hGCAP1-
(P50L) was puri¢ed using G2 a⁄nity chromatogra-
phy [15,33]. Proteins were puri¢ed to apparent
homogeneity as determined by sodium dodecyl sul-
fate^polyacrylamide gel electrophoresis (SDS^
PAGE) and Coomassie staining.
2.4. Expression and puri¢cation of GCAP2-green
£uorescent protein (GFP)
The fusion protein GCAP2-GFP (Dr. Iswari Sub-
baraya, Baylor College of Medicine), GFP fused to
the C-terminus of GCAP2, was expressed in Sf9 in-
sect cells and immunoa⁄nity-puri¢ed by a procedure
analogous to the puri¢cation of GCAP2 [34].
GCAP2-GFP had activating properties indistinguish-
able from GCAP2 (Subbaraya and Palczewski, un-
published).
2.5. GC assays
Washed bovine ROS membranes were prepared
from fresh bovine eyes (Schenk Packing Company,
Stanwood, WA, USA), reconstituted with recombi-
nant GCAPs and assayed as described previously
[15,33]. [Ca2] was calculated using the computer
program Chelator 1.00 [32] and in some experiments
adjusted to higher concentration by increasing the
amount of added CaCl2. The GC assays were per-
formed using [K-32P]GTP and washed ROS or using
recombinant GC1 described previously [15]. The re-
sults of GC assays are an average of two determina-
tions. Similar results were obtained from at least two
di¡erent sets of experiments performed in duplicate.
Due to the instability of the GC system (for details,
see [15]), the absolute values of one series occasion-
ally varied from another by 10^20%, but with pres-
ervation of the ratio between activities of two di¡er-
ent preparations (for example, the activity of GCAP1
versus GCAP2). Because only a limited number of
the test samples could be performed in a single assay
(maximally 24 samples) that always included a rele-
vant control (low, high [Ca2]free and þ GCAP1), the
results are shown without standard deviations.
2.6. Cloning of the long and short forms of human
CaBP1
Full length CaBPs were ampli¢ed by PCR from
human, bovine and mouse retina libraries as de-
scribed previously [1]. The PCR products were
cloned. Human CaBP1 was ampli¢ed using primers
designed based on EST aa363863 (deposited by A.R.
Kerlavage, the Institute for Genomic Research,
Rockville, MD, USA). The 3P-end was ampli¢ed
with primers K2 (5P-CTC CGA GAG GCC TTC
AGA GAA TTC) and Vgt10S (5P-AGC AAG TTC
AGC CTG GTA AG). The reaction was cycled
through 94‡C for 30 s, 68‡C for 1 min. The 5P-end
was ampli¢ed with primers K1 (5P-CCA TCA CCA
TTG GTG TCA AAC TCT C) and T7L (5P-GCT
CTA ATA CGA CTC ACT ATA GGG) through
35 cycles of 94‡C for 30 s, 68‡C for 2.5 min. The
human CaBP1 short form full coding sequence was
ampli¢ed with K57 (5P-CAT ATG GGC AAC TGT
GTC AAG TAT CC) and K7 (5P-CGG CCT CAG
CGG GAC ATC ATC C) through 35 cycles of 94‡C
for 30 s, 68‡C for 1.5 min.
2.7. Cloning of bovine CaBP1
The 5P-end of bovine CaBP1 was cloned by PCR
with primers K85 (5P-AGC CTC CTT CAT GGA
CCC) designed in the 5P-untranslated region (UTR)
of hCaBP1 and K81 (5P-TGG CCA CCC AGG TTC
ATG TT) designed in the coding region of hCaBP1
through 35 cycles at 94‡C for 30 s, 50‡C for 30 s and
68‡C for 2 min. The 3P-end was ampli¢ed by PCR
with primers K77 (5P-AAC ATG AAC CTG GGT
GGC CA) designed in the coding region of human
CaBP1 and K93 (5P-TCG GCG GCT ACA GCG
GG) designed in a region of the 3P-UTR of human
CaBP1 homologous to the mouse CABP1 3P-UTR
through 35 cycles of 94‡C for 30 s, 50‡C for 30 s
and 68‡C for 2 min.
2.8. Short and long form of human CaBP1
The human CaBP1 full coding sequence was am-
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pli¢ed with K57 (5P-CAT ATG GGC AAC TGT
GTC AAG TAT CC) and K7 (5P-CGG CCT CAG
CGG GAC ATC ATC C) through 35 cycles of 94‡C
for 30 s, 68‡C for 1.5 min.
2.9. Cloning of mouse CaBP1
The 5P-end of mouse CaBP1 was cycled with K38
(5P-CCC GAA AGG CGT CTC TCA GCT C) and
T7L (5P-GCT CTA ATA CGA CTC ACT ATA
GGG) through 35 cycles at 94‡C for 30 s, 68‡C for
2 min. The 3P-end of mouse CaBP1 was cycled with
K2 (5P-CTC CGA GAG GCC TTC AGA GAA
TTC) and SP6L (5P-GTG AAT TGA ATT TAG
GTG ACA CTA TAG) through 94‡C for 30 s,
55‡C for 30 s and 68‡C for 1.5 min.
2.10. Cloning of bovine CaBP2
The 5P-end of bovine CaBP2 was cloned by PCR
with primers K33 (5P-GTT TAG GCC CAT CAG
TTC CAC AA) and T7L (5P-GCT CTA ATA CGA
CTC ACT ATA GGG) through 35 cycles of 94‡C
for 30 s, 60‡C for 30 s, 68‡C for 2 min. The 3P-end
was cloned with primers K50 (5P-CGG CCA GAG
GAG ATT GAA GAG) and SP6L through 35 cycles
of 94‡C for 30 s, 68‡C for 2.5 min. The bovine
CaBP2 full coding sequence was ampli¢ed by PCR
on bovine retinal cDNA library with primers K53
(5P-CAT ATG GGA AAC TGT GCC AAG CGG
CC) and K8 (5P-TCA GTG ATG GTG ATG GTG
ATG GCG GGA CAT CAT CCG GAC AAA C)
through 35 cycles of 94‡C for 30 s, 56‡C for 30 s and
68‡C for 2 min.
2.11. Cloning of mouse CaBP2
To amplify the 5P-end of mouse CaBP2, 30 PCR
cycles of 94‡C for 30 s, 68‡C for 2 min were run with
primers K82 (5P-GCT GCC CGG AGC TCC CCT
AC) and T7L (5P-GCT CTA CTC ATA CGA ACT
ATA GGG). The 3P-end of mouse CaBP2 was
ampli¢ed with primers K74 (5P-CAG CAA ATC
AGT GGC GGN AA) and SP6L (5P-GTG AAT
TGA ATT TAG GTG ACA CTA TAG) through
35 cycles of 94‡C for 30 s, 54‡C for 30 s and 68‡C
for 2.5 min.
2.12. Cloning of human CaBP2
The 3P-end of human CaBP2 was ampli¢ed with
primers SP6L (5P-GTG AAT TGA ATT TAG GTG
ACA CTA TAG) and K74 (5P-CAG CAA ATC
AGT GGC GGN AA) 35 times at 94‡C for 30 s,
54‡C for 30 s and 68‡C for 2.5 min. Part of the 5P-
end of human CABP2 was ampli¢ed by PCR with
primers T7L (5P-GCT CTA ATA CGA CTC ACT
ATA GGG) and K75 (5P-CTT CCC GCC ACT
GAT TTG CTG) through 35 cycles of 94‡C for
30 s, 54‡C for 30 s and 68‡C for 2 min. The 5P-end
of human CaBP2 was obtained through sequencing
of a BAC genomic clone covering the human CaBP2
gene.
2.13. Cloning of human CaBP3
To amplify the 5P-end of human CaBP3, 35 cycles
at 94‡C for 30 s, 68‡C for 2 min were run with prim-
ers K13 (5P-TTT GAC ACG ATT GGA GAT GGG
GAG) and Vgt10S (5P-AGC AAG TTC AGC CTG
GTA AG) and the 3P-end of human CaBP3 with
primers K11 (5P-CCT CTG CTT TAA GGG GAT
CTG GG) and Vgt10S (5P-AGC AAG TTC AGC
CTG GTA AG). Primers K11 and K13 were de-
signed based on EST W22993 clone (deposited by
Dr. J. Nathans, Johns Hopkins School of Medicine,
MD, USA).
2.14. Cloning of human CaBP5
The 3P-end of human CaBP5 was cycled 94‡C for
30 s, 55‡C for 30 s, and 68‡C for 2 min with primers
K36 (5P-CTG AAA AGC AGC GGG AGA GAC
CA) and Vgt10S (5P-AGC AAG TTC AGC CTG
GTA AG). The 5P-end of human CaBP5 was ampli-
¢ed with primers K37 (5P-CCC ATC GTT CTC
ATG AGA TTG CC) and T7L (5P-GCT CTA
ATA CGA CTC ACT ATA GGG) through 94‡C
for 30 s, 60‡C for 30 s and 68‡C for 2 min.
2.15. Cloning of mouse CaBP5
The 5P-end of mouse CaBP5 was cloned by PCR
with primers K30 (5P-CTC CCC ATC TCC ATT
GGC A) and T7L (5P-GCT CTA ATA CGA CTC
ACT ATA GGG) through 35 cycles at 94‡C for 30 s,
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60‡C for 30 s, and 68‡C for 2.5 min. Primers K27
(5P-GCC AGC AAA TCC GAA TGA ACC TTG)
and SP6L (5P-GTG AAT TGA ATT TAG GTG
ACA CTA TAG) were used to amplify the 3P-end
of mouse CaBP5 following the same PCR conditions.
2.16. Cloning of bovine CaBP5
The 5P-end of bovine CaBP5 was ampli¢ed with
primers K29 (5P-CTC CCG GAC AAC CTC AGA
GAT C) and T7L (5P-GCT CTA ATA CGA CTC
ACT ATA GGG) at 94‡C for 30 s, 55‡C for 30 s and
68‡C for 2 min. The 3P-end of bovine CaBP3 was
cycled at 94‡C for 30 s, 68‡C for 2 min with primers
K27 (5P-GCC AGC AAA TCC GAA TGA ACC
TTG) and SP6L (5P-GTG AAT TGA ATT TAG
GTG ACA CTA TAG).
2.17. CaBP gene structures and expression pro¢les
The CaBP1^5 gene structures and expression pat-
terns were determined as previously described [1].
2.18. Chromosomal localization of CaBP2 and
CaBP3/5 by £uorescence in situ hybridization
The localization of CaBP2 and CaBP3/5 was car-
ried out by Hillary Heins from Genome Systems,
Inc., by £uorescence in situ hybridization as de-
scribed previously [1]. For example, to determine
the location of the CaBP3/5 gene, DNA from clone
F848 was labeled with digoxigenin dUTP by nick
translation. Labeled probes were combined with
sheared human DNA and hybridized to normal
metaphase chromosomes derived from PHA-stimu-
lated peripheral blood lymphocytes from a male do-
nor in a solution containing 50% formamide, 10%
dextran sulfate, and 2USSC. Speci¢c hybridization
signals were detected by incubating the hybridized
slides in £uoresceinated anti-digoxigenin antibodies
followed by counterstaining with DAPI. The initial
experiment resulted in speci¢c labeling of the distal
long arm of a group F chromosome. A second set of
experiments was conducted in which a genomic clone
from the E2A locus (19p13.3) was co-hybridized with
clone F848. This experiment resulted in the speci¢c
labeling of the short and long arms of chromosome
19. Measurements of 10 speci¢c hybridized chromo-
somes 19 demonstrated that F848 is located at chro-
mosome 19q13.3. A total of 80 metaphase cells were
analyzed for each clone with 75 exhibiting speci¢c
labeling.
2.19. Expression of CaBPs in Escherichia coli
The coding sequence for the long and short human
CaBP1 was ampli¢ed from human retina cDNA li-
brary as described above under cloning of short hu-
man CaBP1. The coding sequence for the bovine
CaBP1 was ampli¢ed from bovine retina cDNA li-
brary with primers K53 (5P-CAT ATG GGA AAC
TGT GCC AAG CGG CC) which placed an NdeI
site on the ATG and K8 (5P-TCA GTG ATG GTG
ATG GTG ATG GCG GGA CAT CAT CCG GAC
AAA C) which added a His6-tag at the C-terminus of
the protein. The PCRs were cycled 35 times at 94‡C
for 30 s, 56‡C for 30 s, 68‡C for 2 min. The coding
sequence for mouse CaBP5 was ampli¢ed from
mouse retina cDNA library with primers K42 (5P-
CAT ATG CAG TTT CCA ATG GGT CCT G)
and either K16 (5P-TCA GCG AGA CAT CAT
CTT CAC AAA C) or K17 (5P-TCA GTG ATG
GTG ATG GTG ATG GCG AGA CAT CAT
CTT CAC AAA CTC) which added a His6-tag at
the C-terminus of the protein. The reactions were
cycled 35 times through 94‡C for 30 s, 60‡C for 30
s, and 68‡C for 1.5 min. The short form of mouse
CaBP5 was ampli¢ed with primers K60 (5P-CAT
ATG GGT CCT GCC TGC ATC TTC) and K16
(5P-TCA GCG AGA CAT CAT CTT CAC AAA C)
at 94‡C for 30 s, 60‡C for 30 s and 68‡C for 1.5 min.
The PCR product for each CaBP was cloned in
pCRII-TOPO vector and sequenced by dyedeoxyter-
minator sequencing (ABI-Prism, Perkin-Elmer). The
coding sequences were cloned as fragments NdeI^
BamHI in pET-3b vector (Novagen). CaBPs were
expressed in BL21 bacteria after induction with
0.2 mM IPTG.
2.20. Expression of CaM
The coding sequence for sea urchin CaM was am-
pli¢ed by PCR with primers K30 (5P-CAT ATG
GCT GAC CAA CTC AC) and K24 (5P-TCA
GTG ATG GTG ATG GTG ATG CTT AGC
CGT CAT CAT TTG CAC A), which inserted a
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NdeI restriction site on the ATG and a His6-tag at
the C-terminus of the protein. The reactions were
cycled 35 times through 94‡C for 30 s, 54‡C for
30 s, 68‡C for 1 min and the PCR product was
cloned in pCRII-TOPO vector and sequenced by
dyedeoxyterminator sequencing (ABI-Prism, Perkin-
Elmer). The coding sequence was then transferred as
a fragment NdeI^BamHI in pET-3b vector (Nova-
gen). CaM was expressed in BL21 bacteria after in-
duction with 0.2 mM IPTG and puri¢ed on Ni2-
NTA column.
2.21. Puri¢cation of recombinant calcineurin
All puri¢cation steps were carried out at 4‡C.
Calcineurin was over-expressed in E. coli [35] and
the construct has been obtained from Dr. Jun O.
Liu. Bacteria cell pellet was ultrasonicated in
10 mM BTP, pH 7.5, containing protease inhibitors,
centrifuged and supernatant was loaded on Ni2-
NTA resin. Column was washed with 50 mM
NaH2PO4, pH 8.0, containing 300 mM NaCl and
His6-tagged calcineurin was eluted by 250 mM imi-
dazole in 50 mM NaH2PO4, pH 8.0 with 300 mM
NaCl. Fractions with the highest amount of calci-
neurin were pooled, dialyzed against 10 mM BTP,
pH 7.5, containing 3 mM CaCl2 and loaded on an
equilibrated CaM-Sepharose column. The resin was
washed with 10 mM BTP, pH 7.5, and 500 mM
NaCl. Proteins were eluted with 10 mM BTP, pH
7.5, containing 5 mM EDTA. After analysis of pu-
rity of proteins on 12% SDS^PAGE, fractions con-
taining the recombinant calcineurin were pooled, di-
alyzed and stored at 320‡C before used for future
experiments.
2.22. Direct assay for Ca2+-binding
Ca2-binding parameters were obtained by the
equilibrium dialysis method using an Equilibrium
Dialyzer (Amica, Columbia, MD, USA). The appa-
ratus consisted of two £uid-containing chambers
(protein and bu¡er chambers) separated by a thin
dialysis membrane (molecular mass cuto¡, 5 kDa).
The protein chamber contained 200 Wl of 0.27 Wg/Wl
GCAP2, 0.45 Wg/Wl GCAP1 or 0.09 Wg/Wl
GCAP1(P50L) in 10 mM BTP, pH 7.5, with 150
mM NaCl plus addition of 45Ca2 (1 WCi). The bu¡-
er chamber contained 200 Wl of this same bu¡er ex-
cluding any proteins and 45Ca2 plus the addition of
a known amount of cold Ca2. The £uid in the two
chambers was allowed with rotation to come to equi-
librium after 12 h at 25‡C. Fifteen di¡erent dialysis
experiments were performed at various cold Ca2
concentrations (0, 0.1, 0.3, 1, 3, 9, 30, 90, 150, 300
WM).
2.23. Preparation of [33P]phosphopeptide
The synthetic peptide (DLDVPIPGRFDRRVS-
VAAE) (V2 mg), corresponding to the segment of
the RII subunit of cAMP-dependent kinase (cAMP-
dependent protein kinase (Promega)), was radioac-
tively labeled by 33P on the serine residue, using cat-
alytic subunit of cAMP-dependent protein kinase
(2500 U) and 6 mM ATP with [Q-33P]ATP (107 700
cpm/nmol) as a substrate. Reaction was carried out
for 2 h at 30‡C, in 10 mM BTP, pH 7.5, with 10 mM
MgCl2 (total volume 1 ml). The time course of phos-
phorylation was followed by ¢lter paper technique
using P-cellulose paper in 75 mM H3PO4 to wash
out the excess of [Q-33P]ATP from the phosphorylat-
ed peptide [36].
2.24. Puri¢cation of [33P]phosphopeptide
First, peptide mixtures were puri¢ed on Ga3-im-
mobilized a⁄nity metal ion chromatography
(IMAC) to separate phosphorylated/unphosphory-
lated peptides [37]. After equilibration with 0.1%
CH3COOH of GaCl3 (Alfa Aesar, #35698) charged
chelating Sepharose gel (Pharmacia, #17-0575-01),
peptides were loaded on the resin. Unbound peptides
were removed by exhaustive wash with 0.1%
CH3COOH and 33P-labeled phosphopeptides were
eluted with 1 M NH4OH. Next, the Ga3 IMAC-
puri¢ed phosphopeptides were injected onto a C18
high performance liquid chromatography column
(4.6U150 mm, Hewlett Packard XDB-C18). Peptides
were eluted employing a linear gradient from 0% to
50% CH3CN with 0.05% TFA during 30 min at a
£ow rate of 1 ml/min. The absorbance at 220 nm was
monitored, and a small aliquot (2 Wl) from each frac-
tion was used for counting of 33P activity. Fractions
with the highest activity were dried down using a
SpeedVac.
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2.25. Phosphatase assay
Stimulation of calcineurin (0.05 Wg) by CaBPs was
determined by dephosphorylation of phosphopeptide
(100 000 cpm/nmol) in 50 Wl reaction volumes. De-
phosphorylation was performed in the presence of
20 mM Tris, pH 8.0, 100 mM NaCl, 6 mM MgCl2,
0.5 mM dithiothreitol, 0.1 mM CaCl2 and calcineur-
in stimulators (CaM or CaBPs) for 20 min at 30‡C.
The reactions were terminated by addition of 30 Wl
Fig. 2. P50L and Y99C mutations in GCAP1. A: Sequence alignment of the N-terminal portion of GCAPs and frog GCIP. Y99C is
conserved in all GCAPs. P50L is conserved only in GCAP1 from various species. Numbers in the query column refer to links to the
GenBank. The query sequence was mouse GCAP1 (mGCAP1). B: Three-dimensional model of GCAP1 indicating the location of
P50L and Y99C. The model was generated as described in Section 2.
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acetic acid and the released 33P was washed out from
the peptide using P-cellulose paper in 75 mM H3PO4.
Data were expressed as the number of pmol of re-
leased 33P in 1 min.
2.26. Models of CaBPs
Homology models of human CaBP1, bovine
CaBP2 and human CaBP5 were created on the basis
of the crystal structure of human CaM in its Ca2-
bound state (PDB entry: 1CLL at 1.75 Aî resolution
[38]), making use of the sequence alignment between
these proteins [14]. Because the N-terminal end of
CaM is signi¢cantly shorter than the N-terminus of
the human CaBPs, residues 1^19 of human CaBP1
and residues 1^22 of human CaBP5 were omitted
from the model. The models were generated with
the HOMOLOGY module of the INSIGHT II soft-
ware (Molecular Simulations, Inc., San Diego, CA,
USA) using established homology modeling proto-
cols [39]. In short, protein backbone coordinates
were taken from CaM for all helices, strands, EF
hands and loops with identical lengths. Coordinates
of conserved side chains were kept. Non-conserved
side chains were built from a rotamer database. The
four residues insertion in the long central helix of the
CaBPs between the two domains of the proteins was
assumed not to distort or cause signi¢cant bending
of this structural element. Therefore, the residues
were built in helical conformation. Experimental sup-
port for this approach comes from a mutation study
with CaM in which two residues were deleted from
the central helix. A crystal structure showed only
helix shortening leading to a di¡erent separation of
the two protein domains and a change in relative
orientation of the domains [40]. Coordinates for the
loop with the one residue insertion were obtained by
transplantation from an appropriate PDB entry. Fi-
nally, 2000 steps of conjugate gradient energy mini-
mization were executed to alleviate small irregular-
ities in the structure.
2.27. Homology model of GCAP1
GCAP models were created on the basis of the
crystal structure of unmyristoylated recoverin (PDB
entry: 1REC [41]), making use of the alignment from
[14,15]. The model was created with the HOMOL-
OGY module of the INSIGHT II software (Molec-
ular Simulations, Inc., San Diego, CA, USA) using
established homology modeling protocols [39]. In
short, protein backbone coordinates were borrowed
from recovering for all helices, strands, EF hand
motifs, and loops with identical lengths. The coordi-
nates for other loops were transplanted from appro-
priate PDB entries. Coordinates of conserved side
chains were kept. Non-conserved side chains were
built from a rotamer database. Finally, 2000 steps
of conjugate energy minimization were executed to
alleviate small irregularities in the structure.
Fig. 3. GC stimulation by GCAP1 and recombinant GCAP1 mutants as a function of free Ca2. A: Ca2 titration of GC activity in
washed ROS membranes in the presence of 0.5 Wg bGCAP1, and 0.5 Wg hGCAP1P50L. Inset, the activity of ROS-GC in 40 nM and
1 WM Ca2 without GCAP (black), with bGCAP1 (white) and with hGCAP1P50L (gray). B: Ca2 titration of recombinant bGC1 ac-
tivity in presence of GCAPs (0.5 Wg).
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3. Results
3.1. Biochemical properties of GCAP1(P50L)
Compared with native GCAP1, the previously de-
scribed GCAP1(Y99C) mutant [31] showed a charac-
teristic change in Ca2 sensitivity as a gain of func-
tion [31,42]. The mutated residue Y99, £anking the
EF3 hand (Fig. 2A,B), is highly conserved among
GCAPs and other CaBPs. Its replacement by Cys
lowers the a⁄nity for Ca2-binding to the EF3
loop [31,42]. Another mutation, P50L, was identi¢ed
recently and suggested to be associated also with
autosomal cone dystrophy [59]. P50, in contrast to
Y99, is located in a relatively variable region between
EF1 and EF2, and only conserved among GCAP1s
of various species (Fig. 2A). To investigate whether
the replacement of P50 by L changes the biochemical
properties of the mutant GCAP1, we tested the re-
combinant bovine and human GCAP1(P50L) mu-
tants for their ability to stimulate GC as a function
of Ca2. For most assays, we used native bovine
ROS as sources of GC activity [43]. However, be-
cause ROS preparations most likely contain a mix-
ture of GC isoforms, we used also recombinant bo-
vine and human GC1 expressed in HEK293 cells. We
found that GCAP1(P50L), similarly to GCAP1, ac-
tivates photoreceptor GC at [Ca2]6 100 nM and
inhibits it at micromolar concentrations (Fig. 3A,
inset). GCAP1(P50L) and GCAP1 are identical in
stimulation of ROS-GC in a range of free [Ca2]
from 4 nM to 2 WM (Fig. 3A). Ca2 dependencies
of recombinant GC1 stimulation by GCAP1 and
P50L mutants were comparable to those obtained
for ROS-GC (Fig. 3B). In addition, human and bo-
vine GCAP1(P50L) activated photoreceptor GC to
Fig. 4. Reconstitution of GC activity (A) in ROS membranes and (B) recombinant bGC1. A and B: Reconstitution of GC with 0.5 Wg
bGCAP1 b, hGCAP1 a, bGCAP1P50L S and hGCAP1P50L P as % of maximum stimulation. C: Competition in high Ca2 be-
tween indicated concentrations of bGCAP1 and 0.5 Wg of bGCAP1(P50L). D: Dose-dependent stimulation of ROS-GC by GCAP2
and mixture of GCAP2 with GCAP1(P50L).
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the same relative extent as native GCAP1. Both stim-
ulate GC activity in a dose-dependent fashion with
half-maximal activation occurring at V100 nM and
saturation at V200 nM (Fig. 4A,B). These results
indicate that Ca2-dependent stimulation of GC by
GCAP1(P50L) and GCAP1 are indistinguishable.
In addition to stimulation of GC by Ca2-free
GCAP, we also tested inhibition of basal GC activity
by Ca2-bound GCAPs [43]. GC activity is unaf-
fected by up to 2 WM [Ca2]free, but is V50% inhib-
ited by the Ca2-loaded form of GCAP1.
GCAP1(P50L) inhibition of basal activity is nearly
identical (Fig. 4C), and dose dependence is compa-
rable with that of activation. These data suggest that
GCAP1(P50L) inhibits photoreceptor GC with these
same enzymatic properties as native GCAP1. We
further tested cooperativity of GC stimulation in
the presence of GCAP2, but did not observe any
changes in GC activity regulation in its presence
(Fig. 4D).
3.2. Distinct properties of GCAP1(P50L)
To further investigate the in£uence of the P50L
mutation on biochemical properties of GCAP1, we
measured Ca2-binding parameters by equilibrium
dialysis. Ten WM mutant GCAP1 (or control
GCAPs) was incubated with 0^300 WM 45Ca2 in a
Fig. 5. Alignment of the deduced amino acid sequences of human (h), bovine (b), mouse (m) CaBPs with hCaM. The numbers in the
column identifying the polypeptides refer to GenBank accession numbers. Identical residues or conservative substitutions in at least 13
of 14 sequences are shown in white letters on black background. The conservative substitutions are Q = E = D = N; S = T = A;
V = M = I = L; K = R; Y = W = F. Arrow heads indicate intron^exon junctions for the human CaBP1 gene (presumably conserved in
other mammalian genes). L and S indicate the long or short spliced forms of CaBPs. Note that EF2 is present only in CaM.
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dialysis chamber, and the uptake of calcium mea-
sured after 24 h of equilibration. The results show
that the apparent dissociation constants for Ca2-
binding in normal and mutant GCAPs are nearly
identical (5.2 and 5.6 WM for GCAP1 and
GCAP1(P50L), respectively), while the number of
Ca2-binding sites in mutant GCAP1 is signi¢cantly
reduced (2.9 sites for GCAP1 vs. 1.4 sites for
GCAP1(P50L)). Approximately 3 mol of Ca2
bound to GCAP1 is consistent with the presence of
three functional EF hands in the native polypeptide
(Fig. 1B). Reduction to less than two sites in
GCAP1(P50L) indicates most likely impaired Ca2-
binding in EF2, the site nearest to the P50L muta-
tion. In other mutants disabling Ca2-binding to the
EF2 loop, EF2 was shown to be unimportant for
Ca2-dependent stimulation of GC [33], consistent
with a lack of distinction in Ca2-dependent GC
stimulation by the mutant GCAP1 (Fig. 3B). Inabil-
ity to bind free Ca2 could lead to changes in cone
photoreceptor Ca2 homeostasis and thus trigger a
slow cone degeneration.
Fig. 6. Chromosomal localization and organization of human CaBP genes. A: Gene structures of CaBP1,2 and CaBP4,5. The coding
regions of the CaBP2 gene are shown as black boxes, non-coding regions of exon 1 and exon 6 are shown as white boxes. Introns are
shown as lines. The scales are in base pairs. FISH of CaBP2 (B) and CaBP5 (C) gene probes to human metaphase chromosomes.
The arrow indicates speci¢c labeling on chromosome 11q13.1 and 19q13.3 for CaBP2 and CaBP5, respectively. The respective chro-
mosomes are depicted on the right. Disease loci identi¢ed near the CaBP loci are indicated (for details and references, see http://
www.sph.uth.tmc.edu/RetNet/disease.htm. Boxes indicate correlation of a gene locus to a cloned gene (bVphin, bestrophin; ROM1,
rod membrane protein 1; myoV7A, unconventional myosin 7A; CRX, cone-rod homeobox gene).
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3.3. Novel subfamily of CaBPs
Five novel neuron-speci¢c CaBPs, CaBP1^CaBP5,
were recently cloned ‘in silico’ and subsequently from
retinal libraries [1]. These proteins display a new
combination of functional/non-functional EF hand
motifs and presence/absence of N-terminal myristoy-
lation. Amino acid alignment and dendrogram of
CaM-like CaBPs (Fig. 5) showed that the major
divergence of CaBPs from the common ancestor,
likely a CaM-like protein with four EF domains, is
the inactivation of the second Ca2-binding loop.
Inactivation is accomplished by mutations and dele-
tions of residues important for Ca2 coordination, or
Fig. 7. Tissue distribution of CaBP mRNAs by dot blot analysis. RNA dot blot containing normalized amounts of 89^514 ng of
poly(A) RNA from various human tissues was probed with a 32P-labeled human CaBP1 cDNA (A), human CaBP2 (B) or human
CaBP3 (C) cDNA. D shows the tissue origin of poly A RNA from the master blot.
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alternative splicing. In addition to EF2 inactivation,
CaBP1 contains a consensus sequence for myristoy-
lation not present in CaM. A large portion of the
CaBP1 sequence is identical to previously published
caldendrin [27] and calbrain [44]. We assume that
caldendrin contains additional sequence at the N-ter-
minus that resulted from alternative splicing, while
calbrain represents a truncated sequence of CaBP1.
Retina-speci¢c CaBP2 appears to be a minor com-
ponent in the retina, also is presumably myristoy-
lated and has a 3-amino acid deletion in the EF2
loop rendering it non-functional for Ca2-binding.
In contrast to CaBP1 and CaBP2, the N-terminus
of CaBP5 carries no consensus sequence for myris-
toylation (Fig. 5). The N-terminal exon of the CaBP4
gene has not been unambiguously identi¢ed [1].
3.4. CaBP5/CaBP2 gene structures and chromosomal
localization
CaBPs have gene structures almost identical to
CaM, with only one intron (ivs3) positioned slightly
di¡erently (Fig. 5). The genes encoding CaBP2 and
CaBP4 are the smallest among CaBPs encompassing
only about 3 kb genomic sequence (Fig. 6A). Well-
conserved CaBP and CaM gene structures suggest
that the CaBPs evolved from a CaM-like ancestral
gene. Fluorescent in situ hybridization (FISH) to hu-
man metaphase chromosomes located the CaBP2
gene to chromosome 11q13.1 (Fig. 6B), while a
CaBP5 probe located this gene on chromosome
19q13.3 (Fig. 6C, [1]). The 11q13.1 locus is very close
to those of Best’s macular dystrophy and Usher syn-
drome 1B for whom the causative genes are known,
and recessive Bardet^Biedl syndrome for which the
gene is still unidenti¢ed. Moreover, the 19q13.3 lo-
cus, near a cone/rod dystrophy locus (CORD2)
linked to a transcription factor gene (CRX), is close
to RP11 and Opa3 involving retinal atrophies for
which the causative genes are unknown (Fig. 6C).
In contrast to S100 CaBPs and the GCAP1/2 gene
array, CaBP genes do not appear clustered on the
same chromosome (the CaBP4 and CaBP2 genes,
both on chromosome 11, are at least 40 kb apart
and not clustered). The nearly identical gene struc-
tures of CaBPs, however, indicate evolutionary rela-
Fig. 8. Three-dimensional model of CaM and CaBP1. Color-coded molecular surface of CaM and CaBP1 according to electrostatic
potential. Panels L and R are rotated 180‡ around the horizontal axis. The panels show that the third and fourth EF hand motifs
contribute to the strongly negative potential on both sides of the molecule. The scale bar above each picture shows the color scheme:
units are in kT/e. Figures were generated as described in Section 2 [61].
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tionship with a common ancestor by gene duplica-
tion events and translocation to di¡erent chromo-
somes.
3.5. Tissue distribution of CaBPs other than retina
Master RNA blots containing poly(A) RNA
from 50 human tissues hybridized with CaBP1 as a
probe showed presence of CaBP1 in whole brain
(A1), occipital lobe (B1) and cerebral cortex (A5).
A weak hybridization signal just above background
(negative control, E. coli DNA, H4) was observed in
the frontal lobe (A6), hippocampus (A7), temporal
lobe (B4) and nucleus accumbeus (B6) (Fig. 7A).
CaBP1 reverse transcription (RT)-PCR products
were observed in retina and cerebellum (data not
shown). Hybridization of the master RNA blots
with the CaBP2 probe is shown in Fig. 7B. No signal
was detected above the background (negative con-
trols H3 and H4). In contrast to CaBP1, CaBP2
and CaBP5 are speci¢cally expressed in the retina
(Fig. 7C). Furthermore, RT-PCR was performed
on total RNA isolated from diverse mouse tissue
and CaBP2 and CaBP5 products were seen only in
retina. As a control, GPDH was ampli¢ed in every
tissue. The CaBP mRNA tissue distribution analyzed
by di¡erent methods consistently shows speci¢c ex-
pression of CaBP2 and CaBP5 in retina. CaBP1
mRNAs are present in retina and also in brain, while
it is a minor transcript in the eye and not observed
elsewhere. The CaBP4 expression pattern was not
determined using this master blot.
3.6. Structural predictions
By computer modeling, we compared the CaBP
structures with those of other CaBPs of known ter-
tiary structure. The four residue insertion in the long
central helix of the CaBPs between the two domains
of the proteins was assumed not to distort or cause
signi¢cant bending of this structural element (Fig. 8).
Therefore, the residues were built in helical confor-
mation. Experimental support for this approach
comes from a mutation study with CaM in which
two residues were deleted from the central helix. A
crystal structure showed only helix shortening lead-
ing to a di¡erent separation of the two protein do-
mains and a change in relative orientation of the
domains [40]. Coordinates for the loop with the
one residue insertion were obtained by transplanta-
tion from an appropriate PDB entry. Finally, 2000
steps of conjugate gradient energy minimization were
executed to alleviate small irregularities in the struc-
ture. These modeling data suggest that CaBPs may
have an overall structure very similar to CaM (Fig.
8).
3.7. In search for function for CaBPs
CaM and CaM-like proteins are multifunctional
and stimulate or inhibit a variety of targets. Several
candidate targets for CaBPs were tested recently [1].
We have established that CaBPs can substitute for
CaM in inhibition of G-protein-coupled receptor ki-
nases, and stimulation of CaM kinase II. Further-
Fig. 9. Dephosphorylation of phosphopeptide by calcineurin in the presence of CaM and CaBPs. Dose-dependent and time course for
CaBPs- and CaM-mediated dephosphorylation by calcineurin as a % of 33P radioactivity at time zero. Assays were performed as de-
scribed under Section 2 and shown data are representative of two separated experiments.
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more, it has been shown that CaBP1 binds avidly to
cytoskeletal proteins [27]. Here, we tested e¡ects on
CaBPs of another enzyme that is stimulated by CaM,
protein phosphatase B-calcineurin [45,46]. A candi-
date approach was also used in a search for possible
e¡ector protein of other CaBPs. Because of potent
activation of calcineurin by CaM and signi¢cant ho-
mology of CaBPs with CaM, we tested CaBPs in
stimulation of phosphatase activity of calcineurin.
A phosphorylated peptide derived from cAMP-de-
pendent protein kinase catalytic subunit [47] served
as a substrate in the calcineurin activity [48]. Peptide
dephosphorylation by calcineurin was increased in
presence of CaM, CaBP2 and CaBP5, and was linear
for up to 40 min (Fig. 9A). However, peptide de-
phosphorylation was less e¡ective in the presence
of CaBP2 and CaBP5 as compared to CaM, and
required higher concentration of CaBPs (Fig. 9B).
CaBP1 had no signi¢cant e¡ect on calcineurin activ-
ity.
Together, these results suggest that CaBP can sub-
stitute for CaM in various assays. However, there is
a clear distinction and speci¢city between di¡erent
CaBPs. Thus, some cellular regulations previously
assigned to CaM may be carried out in vivo by
CaBPs. On the other hand, the in vitro assays are
prone to error, due to dilution of interaction part-
ners, or erroneous choice of the interaction partners
that will not co-localize in vivo. These results must
be further evaluated in independent assays in the
future, including genetic methods.
4. Discussion
Ca2 ions play an important role in the physiology
of all eukaryotes. Over many years, the vertebrate
retina has been a model tissue that has been used
to decipher principles of these regulatory processes.
In particular, Ca2 modulation of phototransduction
events received ample attention, while other regula-
tory mechanisms of the visual system are less well
understood. In the photoreceptor cell, light causes
bleaching and activation of photoreceptor molecules,
which in turn activate a cascade of enzymatic reac-
tions that culminates in cGMP and Ca2 concentra-
tion decreases. In contrast to most neurons, the de-
crease, and not increase, in free Ca2 concentration
is the signal that activates enzymes and proteins of
phototransduction. The most critical event in return
to the dark state is activation of GCs by Ca2-free
GCAPs that leads to restoration of high levels of
cGMP, depleted by the activation of phototransduc-
tion cascade [7].
4.1. The GC/GCAP modulatory system
Two membrane-associated GCs, GC1 and GC2,
were identi¢ed in the mammalian retina [49^51],
regulated by at least three GCAPs (GCAP1^3)
[1,14^16,52]. The multi-domain structure of mem-
brane GCs implies a complex, multi-ligand target
that has only been partially explored. The single sub-
unit GC consists of an extracellular receptor-like
binding domain, a transmembrane segment, a ki-
nase-like domain, a dimerization motif, and a cata-
lytic domain. GCAPs interact with GC through the
intracellular domain [53,54], modulating GC activity.
GCAPs have nearly identical function, but the se-
quence similarity of GCAP3 with GCAP1 and
GCAP2 is only 57% and 49%, respectively. Recombi-
nant GCAP3 and GCAP2 stimulate GC1 and GC2
in low [Ca2]free and inhibit GCs when [Ca2]free is
elevated, unlike GCAP1 which only stimulates GC1.
The intron/exon arrangement of the GCAP3 gene is
identical to that of the other two GCAP genes. How-
ever, while the GCAP1 and GCAP2 genes are ar-
ranged in a tail-to-tail array on chromosome 6p in
human [55], the GCAP3 gene is located on 3q13.1,
suggesting an ancestral gene duplication/transloca-
tion event [52].
Although the tertiary structures of CaBPs contain-
ing multiple EF hand motifs appear remarkably con-
served, their amino acid sequences are quite diver-
gent. Proteins from the CaM superfamily contain
four EF hand motifs, some of which are non-func-
tional due to insertions that alter the spatial arrange-
ments and prevent interaction with Ca2. In each
structure, the four EF hands form two domains:
EF1 and EF2 interact with one another to form
the amino-terminal domain, and EF3 and EF4
form the C-terminal half of the molecule. The back-
bone structure of Ca2-bound GCAP2 is very similar
to that of recoverin and neurocalcin [56], and con-
tains a short U-shaped inter-domain linker that po-
sitions the two domains in close contact with one
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another forming a bi-lobed, globular shape with
pseudo C2 symmetry. Three Ca2 ions are bound
to EF2, EF3 and EF4 of GCAPs, but not to EF1
because the binding loop is distorted from a favor-
able Ca2-binding geometry by C35 and P36 at the
third and fourth positions of the 12 residue loop,
preventing coordination of Ca2. The precise struc-
ture of the physiologically active Ca2-free GCAPs is
presently unknown.
Only GCAPs have been shown to activate photo-
receptor GC in their Ca2-free forms, consistent with
their role in phototransduction [6]. In biochemical
assays, two other GC activators, S100L (also termed
GD-GCAP [57]) and neurocalcin [58], have recently
been shown to activate GC1 in the Ca2-occupied
form in vitro. The physiological signi¢cance of their
GC activation by S100 and neurocalcin is unclear.
4.2. Mutations in GCAP1 causing dominant cone
dystrophy
Cone dystrophies are characterized by progressive
loss of color vision, photophobia, and visual acuity.
The occurrence is relatively frequent, the autosomal
dominant form occurs in approximately one in
10 000 births. Several loci have been identi¢ed in au-
tosomal dominant cone and cone-rod dystrophies.
Those associated with identi¢ed genes include muta-
tions in peripherin/RDS (6p12), GCAP1/2 (locus
GUCA1 on 6p21), GC1 (locus GUCY2D on 17p),
and the transcription factor CRX (19q). A Y99C
mutation in GCAP1 has recently been found to be
associated with autosomal dominant cone dystrophy
[31,42]. The biochemical analysis of GCAP1(Y99)
suggested constitutive activation of GC that was
not properly inactivated by dark levels of Ca2, per-
turbing homeostasis of Ca2 in photoreceptor cells in
the dark, ultimately leading to degeneration of these
cells. As a consequence of the GCAP1(Y99) muta-
tion, the Ca2 sensitivity of cones, which have high
levels of GCAP1, is markedly altered, causing persis-
tent stimulation of GC1 under physiological dark
conditions [31]. These results are consistent with a
model in which enhanced GC activity in dark-
adapted cones leads to elevated levels of cytoplasmic
cGMP.
A second GCAP1 mutation (P50L) was identi¢ed
in several small British families a¥icted with autoso-
mal cone dystrophy [59]. In this study, we focused on
biochemical properties of GCAP1(P50L), a mutation
suspected to cause a milder form of autosomal dom-
inant cone dystrophy. We present evidence that like
GCAP1(Y99) mutant, GCAP1(P50L) has modi¢ed
Ca2-binding properties. The P50L mutation, how-
ever, causes decrease in the maximal number of
bound Ca2 ions from 3 to V2 per GCAP1, without
changing the activity pro¢le. Thus, changes in the
biochemical properties of GCAP1(P50L) are more
subtle than those observed for GCAP1(Y99), and
this observation correlates well with the clinical ob-
servation that the Pro mutation causes a milder form
of the autosomal dominant cone dystrophy.
Due to the location of the P50L mutation, it is
predicted that the major e¡ect will be on the adjacent
EF2 domain and its ability to bind Ca2. The dom-
inant character of this mutation in vivo is unclear
because in all our enzymatic assays, GCAP1(P50L)
appears to be similar to normal GCAP1. One inter-
pretation is that the mutant protein interferes with
uncharacterized Ca2-dependent processes of photo-
transduction ultimately leading to the photoreceptor
dystrophy. Alternatively, the P50L mutation may in-
terfere with dimerization of the native GCAP1 [60],
depleting the amount of GCAP in the outer seg-
ments. Further understanding these pathologies will
provide with additional insights in understanding the
role of GCAPs in the physiology of photoreceptor
cells.
4.3. CaBPs, a novel subfamily of Ca2+-binding protein
In contrast to this biochemically well-de¢ned reg-
ulation of phototransduction, we are only beginning
to understand other Ca2-dependent regulatory pro-
cesses in the retina. Recently, we have identi¢ed ¢ve
homologues genes encoding CaBPs that are ex-
pressed in the mammalian retina. Several members
of this subfamily are also present in other tissues. In
contrast to GCAPs, the function/structure of this
subfamily of CaM-like CaBPs is poorly understood.
Computer-aided prediction of the three-dimensional
structure suggests a close relatedness of CaBPs and
CaM, and in many biochemical assays CaBPs can
substitute for CaM, including stimulation of CaM
kinase II and calcineurin. Because of the importance
of calcineurin and CaM kinase II in many cells, and
BBAMCR 14683 27-11-00 Cyaan Magenta Geel Zwart
I. Sokal et al. / Biochimica et Biophysica Acta 1498 (2000) 233^251 249
ubiquitous expression of several CaBPs, the role of
these proteins appears to be correlated to fundamen-
tal processes in these cells.
5. Note added in proof
Characterization of the GCAP1(P50L) mutants
will also be published in: A cone-rod dystrophy
caused by a destabilization of human GCAP1 by a
proline to leucine mutation, by R.J. Newbold, E.
Dery, S.E. Wilkie, C.E. Walker, N. Srinivasan, S.S.
Bhattacharya, D.M. Hunt and M.J. Warren, Molec-
ular Genetics, in press.
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